Publication:
The future of il-1 targeting in kidney disease

Simple item page
dc.contributor.coauthorAfsar, Baris
dc.contributor.coauthorCovic, Adrian
dc.contributor.coauthorOrtiz, Alberto
dc.contributor.coauthorAfsar, Rengin Elsurer
dc.contributor.departmentN/A
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid110580
dc.date.accessioned2024-11-09T23:37:48Z
dc.date.issued2018
dc.description.abstractInterleukin (IL)-1α and IL-1β are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1β antibodies (canakinumab) and IL-1β traps (rilonacept) are in clinical use to treat these diseases. Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue11
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipInstituto de Salud Carlos III, Red REDinREN [RD 16/0009]
dc.description.sponsorshipFIS [PI16 02057]
dc.description.sponsorshipFEDER funds ISCIII-RETIC RED-inREN [RD16/0009]
dc.description.sponsorshipSociedad Espanola de Nefrologia
dc.description.sponsorshipMinistry of Research and Innovation, CNCS-UEFISCDI within PNCDI III [PN-III-P4-ID-PCE-2016-0908, 167/2017] Research of the authors has been supported by grants from Instituto de Salud Carlos III, Red REDinREN RD 16/0009, FIS AO was supported by FIS PI16 02057, FEDER funds ISCIII-RETIC RED-inREN RD16/0009, Sociedad Espanola de Nefrologia. Adrian Covic was supported by a grant of Ministry of Research and Innovation, CNCS-UEFISCDI, project number PN-III-P4-ID-PCE-2016-0908, Contract number 167/2017, within PNCDI III.
dc.description.volume78
dc.identifier.doi10.1007/s40265-018-0942-2
dc.identifier.eissn1179-1950
dc.identifier.issn0012-6667
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85049575857
dc.identifier.urihttp://dx.doi.org/10.1007/s40265-018-0942-2
dc.identifier.urihttps://hdl.handle.net/20.500.14288/12871
dc.identifier.wos440167900002
dc.keywordsInterleukin-1 receptor antagonist
dc.keywordsFamilial mediterranean fever
dc.keywordsNf-kappa-b
dc.keywordsAnti-il-1-beta monoclonal-antibody
dc.keywordsColchicine-resistant
dc.keywordsAngiotensin-ii
dc.keywordsCrescentic glomerulonephritis
dc.keywordsInflammatory cytokines
dc.keywordsRenal inflammation
dc.keywordsInduced il-1-beta
dc.languageEnglish
dc.publisherAdis Int Ltd
dc.sourceDrugs
dc.subjectPharmacology
dc.subjectPharmacy
dc.subjectToxicology
dc.titleThe future of il-1 targeting in kidney disease
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-1297-0675
local.contributor.kuauthorKanbay, Mehmet

Files

Collections

Publications without Fulltext